YOLFTbeta
30

Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.

301096 · SHE · Healthcare / Drug Manufacturers - General

38.55CNY-1.18 (-2.97%)

Price History

Full chart

Market Stats

Previous Close39.73
Open40.00
Day Range38.41 – 40.00
52-Week Range35.20 – 77.17
Volume1.83M
Market Cap5.38B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.85
Dividend Yield0.00%
Beta0.50
50-Day Avg45.77
200-Day Avg52.40

About

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business covers the principal links of drug discovery, pharmaceutical research, clinical trials, customized research and development and production, and registration applications. Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. was incorporated in 2011 and is headquartered in Hangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEOMs. Jinfang Lou
  • Employees1.41K
  • HeadquartersNo. 159, Oasis Road, Hangzhou, China, 310000, China
  • Websitehttps://www.hzbio-s.com

Leadership

  • Ms. Jinfang LouChairwoman of the Board & GM · b. 1968
  • Mr. Fei JiaDeputy GM & Director · b. 1979
  • Mr. An ChenDeputy General Manager · b. 1974
  • Mr. Shufeng ChenFinancial Officer, Board Secretary & Director · b. 1970
  • Ms. Miao LeiDeputy General Manager · b. 1983

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue156.42M207.25M374.31M607.41M1.02B801.92M677.99M
Growth (%)-+32.50%+80.61%+62.27%+67.51%-21.18%-15.45%
Cost of Revenue59.12M70.85M122.53M198.18M350.74M385.06M410.16M
Gross Profit97.29M136.40M251.78M409.23M666.71M416.86M267.83M
Gross Margin62.20%65.81%67.26%67.37%65.53%51.98%39.50%
Operating Expense46.58M70.55M126.66M248.39M368.80M400.46M293.56M
Operating Income50.71M65.85M125.12M160.84M297.91M16.40M-25.74M
Operating Margin32.42%31.77%33.43%26.48%29.28%2.05%-3.80%
EBITDA65.55M85.16M158.09M256.72M393.28M126.68M87.52M
EBITDA Margin41.91%41.09%42.24%42.26%38.65%15.80%12.91%
Net Income44.40M57.40M111.09M194.16M271.97M-52.74M-90.40M
Net Income Margin28.38%27.70%29.68%31.97%26.73%-6.58%-13.33%
R&D15.67M33.50M81.14M166.07M241.02M318.29M189.87M
R&D as % of Total Revenue10.02%16.17%21.68%27.34%23.69%39.69%28.00%
Interest Expense1.78M638.97K3.67M1.32M7.00M16.94M21.02M
Interest Expense % of Total Revenue1.14%0.31%0.98%0.22%0.69%2.11%3.10%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets378.63M658.75M2.92B2.93B3.67B3.72B3.69B
Total Liabilities99.89M319.20M607.10M447.45M984.97M1.14B1.20B
Total Equity278.45M339.56M2.32B2.48B2.68B2.58B2.49B
Cash188.82M133.62M2.01B1.24B881.93M428.97M292.60M
Net Debt-20.62M---175.11M407.52M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow71.47M54.36M145.42M259.41M90.45M-195.86M-154.64M
Capital Expenditure106.95M255.12M248.45M591.58M688.60M395.10M97.92M
Free Cash Flow-35.48M-200.76M-103.02M-332.16M-598.15M-590.96M-252.56M
Dividends Paid13.86M8.73M10.13M66.55M92.81M48.77M20.52M
FCF to OCF-49.65%-369.31%-70.84%-128.04%-661.28%301.73%163.32%
Dividend Paid to FCF-39.07%-4.35%-9.83%-20.04%-15.52%-8.25%-8.13%

Earnings

Report DateMar 14, 2022Apr 25, 2022Aug 9, 2022Oct 25, 2022Mar 12, 2023Apr 27, 2023Aug 9, 2023Oct 25, 2023Dec 31, 2023Apr 22, 2024Jun 30, 2024Oct 28, 2024Dec 31, 2024Apr 22, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------
EPS Actual0.430.180.610.560.460.320.780.760.650.460.780.07-1.79-0.240.270.03-0.890.12-0.10
Surprise-------------------
TimingAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-market-Pre-market-Pre-market-After-hours-----

Key Statistics & Ratios

Market Cap5.38B
Enterprise Value6.13B
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.28
Price / Book2.32
EPS-0.85
Book Value22.98
Revenue (TTM)650.08M
Gross Profit (TTM)236.14M
EBITDA54.74M
Profit Margin-14.14%
Operating Margin-16.81%
Return on Equity-3.62%
Return on Assets-1.71%
Shares Outstanding109.23M
Shares Float84.33M
Beta0.50
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20241×
0.30Jun 3, 2024
20231×
0.80May 4, 2023
20221×
0.60Apr 18, 2022